Corporate Profile

Tivic Health Systems, Inc. is a commercial-stage bioelectronic medicine company focused on treating diseases and conditions by modulating the electrical signals carried along various nerve pathways.

Our first FDA-approved product, ClearUP® Sinus Pain Relief (“ClearUP”), is a patented handheld device that uses ultra-low current electrical waves to relieve sinus pain and congestion, common symptoms of sinus and nasal inflammation. These symptoms are often associated with nasal allergies, sinus infections, chronic sinusitis, cold and flu, a $9.9 billion U.S. market currently dominated by pharmaceutical companies. ClearUP, a non-invasive bioelectronic therapy, can safely and comfortably deliver therapeutic benefits with no significant side effects.

ClearUP is a US FDA Class II and EU Class IIa medical device that has received three regulatory clearances: (US FDA 510(k) number K182025, US FDA De Novo number DEN200006 and EU CE Mark Certificate number CE 704687). ClearUP is available on Amazon, Best Buy, Walgreens, Walmart and other major e-commerce websites.

Investor Relations:

Hanover International
Jim Hock

View and download 2024 Investor Deck:

Previous slide
Next slide

Recent Press

SEC Filings

Q3 2022 Earnings Call ​

Q1 2022 Earnings Call

On May 13, 2022, Tivic Health Systems’ held its second shareholder update conference call. Tivic’s Chief Executive Officer, Jennifer Ernst, presented the Q1 2022 results of operations and the company’s progress since its IPO last November.

Key Corporate Advisors

Investor Relations:

Hanover International
Jim Hock

Media Relations:


Independent Registered
Public Accounting Firm:

Rosenberg Rich Baker Berman, P.A.
265 Davidson Ave, Suite 210
Somerset, NJ 08873
Phone: (908) 231-1000

SEC Counsel:

Procopio, Cory, Hargreaves & Savitch LLP
1117 S California Ave, Suite 200
Palo Alto, CA 94304
(650) 645-9000

Shareholder Contact:

Equiniti Trust Company (EQ)
Customer Care Center
(800) 468-9716  or  (651) 450-4064

Overnight Mail:

1110 Centre Point Curve, Suite 101
Mendota Heights, MN 55120-4100


P.O. Box 64874
St. Paul, MN 55164-0874

Corporate Governance

Audit and Risk Committee

Sheryle Bolton, Chairperson
Karen Drexler
Dean Zikria

Compensation Committee

Karen Drexler, Chairperson
Sheryle Bolton
Dean Zikria

Nominations and Governance Committee

Karen Drexler, Chairperson
Sheryle Bolton
Dean Zikria

Investor Email Alerts

Stay in the know and join our mailing list.

You will receive a verification email. Unsubscribe at any time.

Contact Form